Triple uptake inhibitors: therapeutic potential in depression and beyond (Q28241732)

Expert Opinion on Investigational Drugs

Europe PubMed Central

title

Triple uptake inhibitors: therapeutic potential in depression and beyond (English)

0 references

author name string

Zhengming Chen

series ordinal

1

0 references

Phil Skolnick

series ordinal

2

0 references

language of work or name

English

0 references

publication date

September 2007

0 references

published in

0 references

volume

16

0 references

issue

9

0 references

page(s)

1365-77

0 references

cites work

Pharmacotherapy of depression: a historical analysis

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1365

Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1365

DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1365

Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization.

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1365

Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1365

Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1365

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

The burden of severe depression: a review of diagnostic challenges and treatment alternatives

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Assessing and treating depression in primary care medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

The treatment of depressive states with G 22355 (imipramine hydrochloride).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

New approaches to developing antidepressants by enhancing monoaminergic neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Emerging treatments for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Triple reuptake inhibitors ("broad spectrum" antidepressants).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

"Broad spectrum" antidepressants: is more better for the treatment of depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Dopaminergic-based pharmacotherapies for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Pharmacophore-based discovery of 3,4-disubstituted pyrrolidines as a novel class of monoamine transporter inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Pharmacophore-based discovery, synthesis, and biological evaluation of 4-phenyl-1-arylalkyl piperidines as dopamine transporter inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365

Milnacipran and selective serotonin reuptake inhibitors in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1365